Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 1019 Results
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance
Published in the Journal of Managed Care and Specialty Pharmacy, this study found that low-income and non-white individuals participating in commercial health plans have lower usage of specialty…
New Research Demonstrates Disproportionate Access to Specialty Drugs by Wage and Race
A review of employer-sponsored health plan data found that non-white and low-wage workers may struggle to access specialty medicines for autoimmune diseases.
New Research Finds Patient Access to Drugs Selected for IRA Is Often High (JAMA Health Forum)
A review of Medicare Part D coverage for 10 drugs in the Medicare Drug Price Negotiation Program raises concerns about how program implementation may impact patient access.
Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program
Published in JAMA Health Forum, this study examined current Medicare beneficiary access to the drugs selected for the first round of the Inflation Reduction Act’s Medicare Drug Price Negotiation…
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (DPNP) may lead to fewer subsequent indications and delay launches for small molecule drugs, according to new research from…
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…
ICER’s UPI Report: Unsupported Policy Information
The 2023 iteration of ICER's Unsupported Price Increase report is misguided at best and harmful to patients and society at worst. NPC outlines why the report should not be used to determine policy or…
Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
Three Takeaways from CMS's Patient-Focused Listening Sessions: Toward Improved Patient Engagement
CMS hosted patient-focused listening sessions to discuss the first 10 drugs selected for the Medicare Drug Price Negotiation Program. In this analysis, NPC offers three takeaways to inform…
New Analysis Shows IRA May Lead to Delayed Launches, Fewer Subsequent Indications, and Less Evidence Generation
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
Why It Is Critical to Include Dynamic Drug Pricing in Cost-Effectiveness Analysis in a Post-IRA World
The drug price-related provisions of the Inflation Reduction Act make the case for including dynamic drug pricing in cost-effectiveness analysis even more compelling.